Posters presented at the 2023 Fall Clinical Dermatology Conference evaluated how label warnings may affect new treatment initiation and real-word switching patterns for patients starting risankizumab.
7 Reasons to Not Use MPLS and 4 Better Alternatives Your email has been sent There are a few cases for using MPLS — but most have moved on from multiprotocol label switching and found a cheaper, more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback